Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05197829
Other study ID # H00023559
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 5, 2022
Est. completion date January 5, 2024

Study information

Verified date March 2024
Source University of Massachusetts, Worcester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Continuous glucose monitors can help people with diabetes avoid blood sugar levels that are either dangerously high or low. This study evaluates whether continuous glucose monitoring after discharge from the emergency room can help people with type 1 or type 2 diabetes avoid repeat emergency room visits, achieve improved blood sugar control, and feel less distressed about managing their diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 5, 2024
Est. primary completion date January 5, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Seen in the Emergency Department for hypo- or hyperglycemia - Either an existing diabetes center patient or a new referral - Type 1 or type 2 diabetes - Able to provide informed consent - Fluent in English or Spanish Exclusion Criteria: - Current CGM use - Need for hospital admission - Upcoming CT or MRI within 2 weeks - Pregnancy - Altered mental status - Not appropriate for diabetes center follow up - Prisoners

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Continuous Glucose Monitoring
Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
Other:
Care Coordination
All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.

Locations

Country Name City State
United States UMass Memorial Medical Center Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Mark O'Connor

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Diabetes Distress Diabetes-related distress will be measured via the 17-question Diabetes Distress Scale (DDS). A higher score indicates more diabetes-related distress. The scale ranges from 1 (low distress) to 6 (high distress). Change from emergency room visit to first outpatient follow-up visit (2 or 3 weeks)
Primary Outpatient Clinic Attendance Rate This outcome will measure whether or not each participant attends a subspecialty follow-up appointment as recommended by the emergency room care team. Follow-up visits will generally occur within 2 or 3 weeks
Primary Change in the Problem Areas in Diabetes Score Each participant will fill out the five-question Problem Areas In Diabetes (PAID5) scale. A higher score indicates worse quality of life. Scores range from 0 (good quality of life) to 20 (poor quality of life). Change from emergency room visit to first outpatient follow-up visit (2 or 3 weeks)
Secondary Number of Patients With Repeat Emergency Utilization This metric will include repeat emergency room visits and emergency medical services calls. 6 months
Secondary Change in Hemoglobin A1c Hemoglobin A1c values drawn as part of routine care will be recorded. A positive value indicates that the hemoglobin A1c was lower at follow up than it was at baseline. 6 Months
Secondary Outpatient Visits for Which the CGM Data Changed Management For each patient in the CGM arm, the provider will complete a survey at the time of the initial outpatient follow-up appointment. 2-3 Weeks
Secondary Time In Range For participants in the continuous glucose monitoring arm, we will measure the percentage of time spent with a blood sugar level between 70 and 180 mg/dl. Up to 14 days after the initial emergency visit
Secondary Percentage Time CGM Active For participants in the continuous glucose monitoring arm, we will measure the amount of time the sensor was worn. Up to 14 days after the initial emergency visit
Secondary Number of Sensor Checks Per Day For participants in the continuous glucose monitoring arm, we will measure the number of times per day the sensor was used to check a blood sugar level. Up to 14 days after the initial emergency visit
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A